Avelumab,Axitinib,Cabozantinib,Ipilimumab,Lenvatinib,Nivolumab,Pembrolizumab
Merck,Pfizer,Eisai,BMS
['rcc,(-irccs),(-srcc),(-urcc)']
support the samurai trial testing sabr to rcc primary #asco2023 
GU medical oncologist @UCSanDiego, mom, wife, avid runner. Kidney and prostate cancer research. Tweets are my own and not medical advice.